Most significantly, RBP4, a well-studied adipokine and contributor to insulin resistance in obesity and type 2 diabetes50 and thus a major therapeutic target, was more strongly downregulated following treatment with DEP than T0070907, suggesting that DEP or a derivative may indeed find clinical use as means to reduce insulin resistance in various metabolic diseases. This evidence concerns the gene RBP4 and metabolic disease.